Cargando…

Agomelatine, Ketamine and Vortioxetine Attenuate Energy Cell Metabolism—In Vitro Study

This determination of the mitochondrial effect of pharmacologically different antidepressants (agomelatine, ketamine and vortioxetine) was evaluated and quantified in vitro in pig brain-isolated mitochondria. We measured the activity of mitochondrial complexes, citrate synthase, malate dehydrogenase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ľupták, Matej, Fišar, Zdeněk, Hroudová, Jana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697131/ https://www.ncbi.nlm.nih.gov/pubmed/36430306 http://dx.doi.org/10.3390/ijms232213824

Ejemplares similares

Different Effects of SSRIs, Bupropion, and Trazodone on Mitochondrial Functions and Monoamine Oxidase Isoform Activity
por: Ľupták, Matej, et al.
Publicado: (2023)

Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets
por: Ľupták, Matej, et al.
Publicado: (2021)

Control mechanisms in mitochondrial oxidative phosphorylation
por: Hroudová, Jana, et al.
Publicado: (2013)

Mitochondrial Dysfunctions in Neurodegenerative Diseases: Relevance to Alzheimer's Disease
por: Hroudová, Jana, et al.
Publicado: (2014)

Plasma cortisol in Alzheimer’s disease with or without depressive symptoms
por: Zvěřová, Martina, et al.
Publicado: (2013)

Age-Dependent Alterations in Platelet Mitochondrial Respiration
por: Fišar, Zdeněk, et al.
Publicado: (2023)

Inhibitory effect of celecoxib on agomelatine metabolism in vitro and in vivo
por: He, Jiayang, et al.
Publicado: (2018)

Disturbances of mitochondrial parameters to distinguish patients with depressive episode of bipolar disorder and major depressive disorder
por: Zvěřová, Martina, et al.
Publicado: (2019)

Interactions Among Polymorphisms of Susceptibility Loci for Alzheimer’s Disease or Depressive Disorder
por: Kitzlerová, Eva, et al.
Publicado: (2018)

Agomelatine Attenuates Isoflurane-Induced Inflammation and Damage in Brain Endothelial Cells
por: Cheng, Fang, et al.
Publicado: (2020)

Synthesis and In Vitro Evaluation of N-(Bromobut-3-en-2-yl)-7-methoxy-1,2,3,4-tetrahydroacridin-9-amine as a Cholinesterase Inhibitor with Regard to Alzheimer's Disease Treatment
por: Korabecny, Jan, et al.
Publicado: (2010)

Agomelatine for postpartum depression and breastfeeding
por: Xiao, Le
Publicado: (2021)

Agomelatine's antiglycoxidative action—In vitro and in silico research and systematic literature review
por: Nesterowicz, Miłosz, et al.
Publicado: (2023)

A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine†
por: Montgomery, Stuart A, et al.
Publicado: (2014)

Agomelatine: A novel melatonergic antidepressant
por: Manikandan, S
Publicado: (2010)

Efficacy and tolerability of agomelatine in the treatment of depression
por: Plesničar, Blanka Kores
Publicado: (2014)

Agomelatine Efficacy in the Night Eating Syndrome
por: Milano, Walter, et al.
Publicado: (2013)

Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer’s Disease and Identifying Promising Drug Targets
por: Fišar, Zdeněk
Publicado: (2022)

The Effect of Agomelatine in Behavioral and Psychological Symptoms of Dementia
por: Wang, Carol Sheei-Meei, et al.
Publicado: (2022)

Agomelatine and its therapeutic potential in the depressed patient
por: Kennedy, Sidney H, et al.
Publicado: (2007)

Agomelatine: The evidence for its place in the treatment of depression
por: Eser, Daniela, et al.
Publicado: (2010)

Vortioxetine as adjunctive therapy in the treatment of schizophrenia
por: Redaelli, Sofia, et al.
Publicado: (2022)

Clinical effectiveness of vortioxetine in postcovid syndrome
por: Vikarenko, M., et al.
Publicado: (2022)

Vortioxetine: Clinical Pharmacokinetics and Drug Interactions
por: Chen, Grace, et al.
Publicado: (2017)

Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients
por: Findling, Robert L., et al.
Publicado: (2017)

Pharmacokinetics and Safety of Vortioxetine in the Chinese Population
por: Miao, Jia, et al.
Publicado: (2019)

Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies
por: Taylor, David, et al.
Publicado: (2014)

Agomelatine as monotherapy for major depression: an outpatient, open-label study
por: Pecenak, Jan, et al.
Publicado: (2013)

Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies
Publicado: (2014)

Agomelatine: relief ensured at each and every stage of depression
por: Möller, Hans-Jurgen
Publicado: (2010)

A systematic review of agomelatine-induced liver injury
por: Freiesleben, Silka Dawn, et al.
Publicado: (2015)

Potentiation of Antidepressant Effects of Agomelatine and Bupropion by Hesperidin in Mice
por: Nadar, Jegan Sakthivel, et al.
Publicado: (2018)

Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders
por: Savino, Rosa, et al.
Publicado: (2023)

Agomelatine prevents angiotensin II-induced endothelial and mononuclear cell adhesion
por: Hong, Najiao, et al.
Publicado: (2021)

Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
Publicado: (2013)

Vortioxetine hydrobromide inhibits the growth of gastric cancer cells in vivo and in vitro by targeting JAK2 and SRC
por: Li, Mingzhu, et al.
Publicado: (2023)

Clinical efficacy of Vortioxetine and escitalopram in the treatment of depression
por: Shao, Shichuan, et al.
Publicado: (2022)

Crystal structures of vortioxetine and its methanol monosolvate
por: Zhou, Xin-Bo, et al.
Publicado: (2015)

Which Cognitive Domains are Improved by Treatment with Vortioxetine?
por: Harrison, John E, et al.
Publicado: (2016)

Vortioxetine improves cognition in mild cognitive impairment
por: Tan, Sheng Neng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f31lek0h6c8o467vn4tjkknhft